Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of October 2021, with a specific report date of October 19, 2021. The filing announces a significant operational milestone: the full commercial launch in Israel of the first medical cannabis products by Evogene's subsidiary, Canonic Ltd.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity figures. This report serves solely to disclose a corporate event and incorporates a press release by reference.
Material Changes
The primary material change disclosed is the transition of Canonic Ltd. from development or regulatory approval phases to full commercial availability of its medical cannabis products in the Israeli market. No financial comparisons to prior periods are included in this document.
Guidance, Outlook, and Risks
Management commentary regarding financial guidance, future outlook, specific risks, or contingencies is not contained within the body of this Form 6-K. The filing references a press release (Exhibit 99.1) for further details but explicitly excludes statements from the President and CEO of Evogene and the CEO of Canonic from incorporation into registration statements.
Key Facts for Investor Verification
- Verify the commercial launch status and product portfolio of Canonic Ltd. in Israel via the referenced press release (Exhibit 99.1).
- Confirm the impact of this launch on Evogene's overall revenue projections in subsequent quarterly or annual reports.
- Review the subsidiary's regulatory standing and market penetration strategy in the Israeli medical cannabis sector.